These studies highlight the importance of optimal sequencing of TSLPRCART immunotherapy and ruxolitinib in the context of planned phase 1 clinical trials for children and AYAs with relapsed/refractory CRLF2+ leukemias. This evidence concerns the gene CRLF2 and leukemia.